HMGB1 and ovarian neoplasm: Of the 321 evaluable ovarian tumours stained with the HMGB1 specific monoclonal antibody, 43/321 (13%) had weak/absent staining and 278/321 (87%) had positive staining having dichotomised cases into high or low/absent expressing groups.